Effect of sitagliptin monotherapy on serum total ghrelin levels in people with type 2 diabetes

ÖZ GÜL Ö., Kiyici S., ERSOY C., CANDER S., Yorulmaz H., Gul C. B., ...Daha Fazla

DIABETES RESEARCH AND CLINICAL PRACTICE, cilt.94, sa.2, ss.212-216, 2011 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 94 Sayı: 2
  • Basım Tarihi: 2011
  • Doi Numarası: 10.1016/j.diabres.2011.07.031
  • Dergi Adı: DIABETES RESEARCH AND CLINICAL PRACTICE
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.212-216
  • Anahtar Kelimeler: Sitagliptin, Diabetes mellitus type 2, Ghrelin, Body weight, INCRETIN-BASED THERAPIES, CIRCULATING GHRELIN, INSULIN THERAPY, WEIGHT-GAIN, METFORMIN, INHIBITOR, STOMACH, PEPTIDE
  • Bursa Uludağ Üniversitesi Adresli: Evet

Özet

Aim: Sitagliptin is not associated with weight gain and has neutral effects on body weight. It is unclear whether sitagliptin treatment alters serum ghrelin levels in people with type 2 diabetes.